With this we assess the cytotoxic drug sensitivity of fresh human cells from patients with leukaemia, lymphoma and cancer. A report is sent to the physician to aid choice of optimum therapy.
Some assays are chargeable.
A new drug is tested against tumour cells from a variety of diseases as well as normal cells. This can elucidate targets for further clinical Phase II or Phase III trials, provide information about cross-resistance with known cytotoxic drugs and produce an ex vivo therapeutic index. Funding The work of Bath Cancer Research is funded by grants, contracts, sale of services and donations.